BPC-157: what the research actually shows
BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice. Its evidence base is almost entirely rodent studies, mostly from one research group in Zagreb, reporting accelerated tendon, ligament, muscle and gut healing. There are no completed randomised human trials. It is not approved as a medicine anywhere and has been on the WADA prohibited list since 2022.
6 September 2026 · SiamesePeptides
BPC-157 is the most requested compound in the research-peptide market and also the one with the widest gap between what is claimed and what has been demonstrated. This is a summary of the actual literature.
What it is
Body Protection Compound 157 is a synthetic pentadecapeptide: fifteen amino acids, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular mass about 1419 Da. It is a fragment of a larger protein isolated from human gastric juice, first described by Predrag Sikirić’s group at the University of Zagreb in the early 1990s. It is stable in gastric acid, which is unusual for a peptide and is one reason the group has studied it in oral as well as injected forms.
What the animal studies report
The published record runs to several hundred papers, the large majority from the Zagreb group. Recurring findings in rats and mice include:
- Tendon and ligament healing. Faster recovery of transected Achilles tendon and medial collateral ligament, with improved biomechanical strength versus saline controls (Krivic et al., 2006; Staresinic et al., 2003).
- Muscle injury. Improved functional recovery after crush and transection injuries.
- Gastrointestinal protection. Reduced lesion formation in NSAID, alcohol and stress-induced ulcer models, and protective effects in colitis and short-bowel models.
- Angiogenesis and nitric oxide. Increased expression of VEGFR2 and modulation of the nitric-oxide system are the mechanisms most often proposed.
- Fistula and anastomosis healing. Improved closure in several surgical models.
The findings are consistent across studies, which is a strength. Their concentration in a single lab, with few independent replications, is the corresponding weakness that any honest summary has to state.
What the human data shows
Almost nothing. Two phase I safety studies were registered in the 2010s; one, sponsored by a Croatian pharmaceutical company, reported no significant adverse events but was never followed by an efficacy trial. There are no published randomised controlled trials of BPC-157 for any indication in humans. Claims about human outcomes are extrapolated from rodents or drawn from anecdote.
Regulatory status
- United States. The FDA placed BPC-157 in Category 2 of its bulk drug substances list in 2023, citing safety concerns and lack of human data, which prohibits compounding pharmacies from using it.
- WADA. Prohibited at all times under S0 (non-approved substances) since 2022. Athletes subject to testing should treat it as banned.
- UK, EU, Australia. Not licensed as a medicine anywhere. It is sold as a research reagent.
How to read this
BPC-157 has an unusually coherent animal literature and an almost empty human one. That combination is exactly what makes it interesting to researchers and exactly what should stop anyone treating rodent doses as guidance. The material we supply is for laboratory use, and the papers above are the right starting point for designing that use.
Key references
- Sikirić P et al. “Brain-gut axis and pentadecapeptide BPC 157.” Current Neuropharmacology, 2016.
- Krivic A et al. “Achilles detachment in rat and stable gastric pentadecapeptide BPC 157.” Journal of Orthopaedic Research, 2006.
- Seiwerth S et al. “BPC 157 and standard angiogenic growth factors.” Current Pharmaceutical Design, 2018.
- FDA, “Bulk drug substances nominated for use in compounding under section 503A,” Category 2 listing, 2023.